FY2029 Earnings Forecast for ZNTL Issued By HC Wainwright

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, January 29th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.58) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.48) per share.

A number of other equities analysts have also weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, Guggenheim lowered their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Stock Down 12.2 %

NASDAQ ZNTL opened at $1.66 on Friday. Zentalis Pharmaceuticals has a 52 week low of $1.66 and a 52 week high of $18.07. The company has a market capitalization of $118.30 million, a P/E ratio of -0.67 and a beta of 1.86. The stock’s 50-day moving average price is $2.97 and its 200-day moving average price is $3.29.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. American Century Companies Inc. purchased a new position in Zentalis Pharmaceuticals during the second quarter worth $95,000. Bank of Montreal Can bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth about $402,000. Squarepoint Ops LLC boosted its stake in shares of Zentalis Pharmaceuticals by 543.8% during the 2nd quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock worth $608,000 after purchasing an additional 125,649 shares during the period. Algert Global LLC bought a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $78,000. Finally, SG Americas Securities LLC grew its holdings in Zentalis Pharmaceuticals by 84.8% during the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after purchasing an additional 11,997 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.